Modern Healthcare spoke with Lisa Scholz, PharmD, FACHE, Sentry’s Head of Industry Relations, for a recent article, “Drugmakers crackdown on 340B discounts, demand data.”

The article covers the several manufacturer notices and letters to hospitals that pharma companies such as Eli Lilly, Merck and Sanofi have been sending to covered entity hospitals in an effort to limit or undermine the 340B drug discount program.

“These changes are aimed at the contract pharmacy model, and they are aimed at covered entities’ bottom lines. Through those pharmacies, covered entities are able to utilize those savings, and they use the benefits they receive to benefit their patient populations,” Scholz said in the article.

Click here to read more from Scholz on pharma’s recent push against 340B.